PharVision Advisers’s TORM TRMD Stock Holding History

PharVision Advisers’s Portfolio TRMD Stock Details TRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,363	Closed	-$214K	–	1005
2025 Q3	$214K	Buy	+10,363	New	+$209K	0.12%	459

Other funds holding TRMD

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marnell Management Farmington Hills, Michigan $288M AUM

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

PharVision Advisers's TRMD Position: Q4 2025 in Review

PharVision Advisers sold out of TORM (TRMD) in Q4 2025, closing a stake of 10,363 shares — an estimated $214K sold.

PharVision Advisers first reported a position in TRMD in Q3 2025 and held it in 1 quarter. The position peaked at $214K in Q3 2025. 111 funds tracked by Wall St. Rank hold TRMD as of Q4 2025.

PharVision Advisers reported no remaining TORM position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 10,363 TORM shares in Q4 2025, an estimated $214K.
PharVision Advisers first reported a position in TORM in Q3 2025 and held it in 1 quarter.
PharVision Advisers's TORM position peaked at $214K in Q3 2025.
111 funds tracked by Wall St. Rank held TORM as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.